Voyager Therapeutics, INC. (VYGR) — 8-K Filings

8-K Filings (13)

• Voyager Therapeutics Files 8-K — Sep 2, 2025 Risk: low
  Voyager Therapeutics, Inc. filed an 8-K on September 2, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• Voyager Therapeutics Announces Corporate Changes and Filings — Jun 5, 2025 Risk: medium
  Voyager Therapeutics, Inc. announced on June 3, 2025, a series of significant corporate actions. These include the departure of certain directors and officers,
• Voyager Therapeutics Files 8-K — May 6, 2025 Risk: low
  On May 6, 2025, Voyager Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 75 Hayden Avenue,
• Voyager Therapeutics Files 8-K on Financials — Mar 11, 2025 Risk: low
  Voyager Therapeutics, Inc. filed an 8-K on March 11, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
• Pfizer to Acquire Voyager Therapeutics for $3.5 Billion — Feb 11, 2025 Risk: medium
  Voyager Therapeutics, Inc. announced on February 11, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for $3.5 billion in cas
• Voyager Therapeutics Enters Material Definitive Agreement — Sep 5, 2024 Risk: medium
  On September 3, 2024, Voyager Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agreement
• Voyager Therapeutics Appoints New CMO and CDO, Burns Departs — Jun 13, 2024 Risk: medium
  Voyager Therapeutics, Inc. announced on June 11, 2024, the appointment of Dr. Todd M. Batson as Chief Medical Officer and Dr. Sarah L. Sell as Chief Development
• Voyager Therapeutics Sets Annual Meeting for June 27 — Jun 6, 2024 Risk: low
  Voyager Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting that its annual meeting of stockholders will be held on June 27, 2024. At this meeting, stock
• Voyager Therapeutics Files 8-K — May 16, 2024 Risk: low
  On May 16, 2024, Voyager Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details rega
• Voyager Therapeutics Appoints New CMO and CDO — Apr 2, 2024 Risk: medium
  Voyager Therapeutics, Inc. announced on March 27, 2024, the appointment of Dr. Sarah Tisch as Chief Medical Officer and Dr. Kevin R. Jones as Chief Development
• Voyager Therapeutics Files 8-K — Mar 13, 2024 Risk: low
  Voyager Therapeutics, Inc. filed an 8-K on March 13, 2024, reporting events as of February 29, 2024. The filing primarily concerns financial statements and exhi
• Voyager Therapeutics Reports Material Definitive Agreement — Jan 8, 2024
  Voyager Therapeutics, Inc. (VYGR) filed an 8-K on January 8, 2024, reporting a material definitive agreement and other events that occurred on January 3, 2024.
• Voyager Therapeutics Files 8-K on Material Agreement & Equity Sales — Jan 2, 2024
  Voyager Therapeutics, Inc. filed an 8-K on January 2, 2024, reporting an event on December 28, 2023, related to an entry into a material definitive agreement, r

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX